MissionIR Articles

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, recently secured approval from the U.S. Food and Drug Administration (“FDA”) for its Suitability Petition to advance KETAFREE(TM), a preservative-free version of ketamine. “The ruling allows the…

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, is advancing a two-pronged approach to bring preservative-free ketamine-based therapies to market, pursuing distinct regulatory and commercial pathways for both KETAFREE(TM) and NRX-100. (https://ibn.fm/BYg97). The company recently…

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has re-filed an Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free intravenous (“IV”) ketamine formulation intended for all currently approved ketamine indications. This follows FDA approval of…

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it has received approval from the U.S. Food and Drug Administration (“FDA”) for its Suitability Petition to advance KETAFREE(TM), a preservative-free version of ketamine (https://ibn.fm/qFzsh). The…

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has re-filed its Abbreviated New Drug Application with the U.S. FDA for KETAFREE(TM), a preservative-free IV ketamine formulation, covering all existing approved indications, following FDA approval of its Suitability…

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that its wholly owned subsidiary HOPE Therapeutics Inc. has closed the acquisition of Dura Medical, a revenue-generating and EBITDA-positive provider of interventional psychiatry services in Naples…

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc. (“HOPE”), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, announced that Chairman and CEO Jonathan Javitt, M.D., M.P.H., will participate in a…

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its intravenous ketamine formulation, NRX-100, for the treatment of suicidal ideation in…

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has submitted a formal Citizen Petition to the U.S. Food and Drug Administration (“FDA”), urging the agency to prohibit the use of benzethonium chloride in all ketamine…

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, reported financial results for the quarter ended June 30, 2025, and provided a corporate update. The Company highlighted progress in all three lead programs, including expanded FDA…

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, Inc., a multi-site clinical care delivery organization, recently signed a binding letter of intent to acquire a 49% stake in Cohen…

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, is accelerating its push toward regulatory approval of NRX-100, a preservative-free intravenous ketamine formulation. The company has filed an…

NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, has engaged IBN to manage its corporate communications strategy. NRx is advancing two FDA-designated therapies—NRX-100 and NRX-101—with an NDA…

NRx Pharmaceuticals (NASDAQ: NRXP) has filed for the newly launched FDA Commissioner’s National Priority Voucher (CNPV) program, seeking accelerated review for NRX-100, its preservative-free intravenous ketamine formulation. The company believes NRX-100 meets all criteria outlined…

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for NRX-100, a preservative-free formulation of ketamine. The submission seeks approval for all existing ketamine…